Ohe Y - Search Results

1

Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.

Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: ohe y. Clin Lung Cancer. 2021 Jul;22(4):282-291.e6. doi: 10.1016/j.cllc.2021.02.003. Epub 2021 Feb 8. Clin Lung Cancer. 2021. PMID: 33722498

2

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, Ueda Y, Akiyama Y, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Kusaba H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2002 Feb;32(2):43-7. doi: 10.1093/jjco/hyf013. Jpn J Clin Oncol. 2002. PMID: 11948227 Clinical Trial.

3

Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A).

Ohe Y, Ishizuka N, Tamura T, Sekine I, Nishiwaki Y, Saijo N; Japan Clinical Oncology Group. Ohe Y, et al. Cancer Sci. 2003 Aug;94(8):729-34. doi: 10.1111/j.1349-7006.2003.tb01510.x. Cancer Sci. 2003. PMID: 12901800 Free PMC article.

4

Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.

Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N. Watanabe H, et al. Among authors: ohe y. Cancer Sci. 2003 Nov;94(11):1015-20. doi: 10.1111/j.1349-7006.2003.tb01394.x. Cancer Sci. 2003. PMID: 14611681 Free PMC article.

5

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Watanabe H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2003 Dec;33(12):626-30. doi: 10.1093/jjco/hyg116. Jpn J Clin Oncol. 2003. PMID: 14769840

6

Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.

Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Sekine I, et al. Among authors: ohe y. Cancer Treat Rev. 2004 Jun;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006. Cancer Treat Rev. 2004. PMID: 15145510 Review.

7

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Takano T, et al. Among authors: ohe y. Lung Cancer. 2004 Jul;45(1):93-104. doi: 10.1016/j.lungcan.2004.01.010. Lung Cancer. 2004. PMID: 15196739 Clinical Trial.

8

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: ohe y. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free PMC article. Clinical Trial.

9

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, Sekine I, Kunitoh H, Ohe Y, Kodama T, Shimizu M, Nishio K, Ishizuka N, Saijo N. Yamamoto N, et al. Among authors: ohe y. J Clin Oncol. 2005 Feb 20;23(6):1061-9. doi: 10.1200/JCO.2005.11.036. Epub 2005 Jan 18. J Clin Oncol. 2005. PMID: 15657405 Clinical Trial.

10

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Takano T, et al. Among authors: ohe y. J Clin Oncol. 2005 Oct 1;23(28):6829-37. doi: 10.1200/JCO.2005.01.0793. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998907

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

722 results

Search Page

Filters